Foa R - Search Results

1

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.

Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. Meloni G, et al. Among authors: foa r. Blood. 1994 Oct 1;84(7):2158-63. Blood. 1994. PMID: 7919330 Free article. Clinical Trial.

2

Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.

Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, Gillio Tos A, Mandelli F, Gavosto F. Foa R, et al. Recent Results Cancer Res. 1993;131:207-14. doi: 10.1007/978-3-642-84895-7_18. Recent Results Cancer Res. 1993. PMID: 8210640 No abstract available.

3

Interleukin 2 treatment in acute myelogenous leukemia.

Mandelli F, Vignetti M, Tosti S, Andrizzi C, Foa R, Meloni G. Mandelli F, et al. Among authors: foa r. Stem Cells. 1993 Jul;11(4):263-8. doi: 10.1002/stem.5530110402. Stem Cells. 1993. PMID: 8401249 Review.

4

Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.

Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Meloni G, et al. Among authors: foa r. Leuk Lymphoma. 1996 May;21(5-6):429-35. doi: 10.3109/10428199609093440. Leuk Lymphoma. 1996. PMID: 9172807 Clinical Trial.

5

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.

Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F. Foa R, et al. Blood. 1991 Aug 15;78(4):1041-6. Blood. 1991. PMID: 1868239 Free article.

6

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.

Foa R, Guarini A, Gillio Tos A, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. Foa R, et al. Cancer Res. 1991 Feb 1;51(3):964-8. Cancer Res. 1991. PMID: 1988139

7

Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F. Foa R, et al. Br J Haematol. 1991 Apr;77(4):491-6. doi: 10.1111/j.1365-2141.1991.tb08615.x. Br J Haematol. 1991. PMID: 2025574

8

IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study.

Meloni G, Foà R, Tosti S, Vignetti M, Gavosto F, Mandelli F. Meloni G, et al. Among authors: foa r. Haematologica. 1990 Nov-Dec;75(6):502-5. Haematologica. 1990. PMID: 2098290

9

Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease.

Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro MT. Foa R, et al. Blood. 1990 Jul 15;76(2):393-400. Blood. 1990. PMID: 2114936 Free article.

10

Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.

Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Guarini A, Cardona S, Gillio Tos A, Gavosto F, Mandelli F. Foa R, et al. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:98-102. Bone Marrow Transplant. 1990. PMID: 2202476 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

937 results

Search Page

Filters